Frova



Indications and Reactions:

Role Indications Reactions
Primary
Migraine 57.1%
Product Used For Unknown Indication 22.2%
Headache 3.2%
Hypertension 3.2%
Tension Headache 3.2%
Accidental Exposure To Product 1.6%
Contraception 1.6%
Depression 1.6%
Drug Exposure During Pregnancy 1.6%
Fibromyalgia 1.6%
Migraine With Aura 1.6%
Surgery 1.6%
Vomiting 12.0%
Retrograde Amnesia 8.0%
Therapeutic Response Unexpected 8.0%
Ventricular Fibrillation 8.0%
Abortion Induced 4.0%
Acute Myocardial Infarction 4.0%
Adverse Event 4.0%
Anaphylactic Reaction 4.0%
Angle Closure Glaucoma 4.0%
Cardiomyopathy 4.0%
Cerebrovascular Accident 4.0%
Dizziness 4.0%
Drug Exposure During Pregnancy 4.0%
Drug Screen Positive 4.0%
Exposure During Pregnancy 4.0%
Food Allergy 4.0%
Headache 4.0%
Incorrect Dose Administered 4.0%
Interstitial Lung Disease 4.0%
Loss Of Consciousness 4.0%
Secondary
Migraine 65.6%
Optic Neuritis 15.6%
Headache 12.5%
Migraine Prophylaxis 6.3%
Cardiomyopathy 20.0%
Throat Tightness 13.3%
Abortion Induced 6.7%
Concomitant Disease Aggravated 6.7%
Drug Hypersensitivity 6.7%
Drug Ineffective 6.7%
Gait Disturbance 6.7%
Headache 6.7%
Venous Stenosis 6.7%
Ventricular Fibrillation 6.7%
Visual Field Defect 6.7%
Vomiting 6.7%
Concomitant
Migraine 22.3%
Product Used For Unknown Indication 19.3%
Depression 5.5%
Pain 5.5%
Contraception 5.3%
Drug Use For Unknown Indication 4.1%
Acne 3.8%
Headache 3.6%
Multiple Sclerosis 3.6%
Anxiety 3.5%
Asthma 3.3%
Hypertension 3.0%
Gastrooesophageal Reflux Disease 2.5%
Nausea 2.5%
Epilepsy 2.2%
Premenstrual Syndrome 2.2%
Hypothyroidism 2.1%
Insomnia 2.0%
Cyclic Vomiting Syndrome 1.9%
Arthritis 1.8%
Weight Increased 9.9%
Deep Vein Thrombosis 7.7%
Vision Blurred 7.7%
Vomiting 7.7%
Neonatal Aspiration 6.6%
Depression 5.5%
Drug Ineffective 5.5%
Headache 5.5%
Nausea 5.5%
Tremor 5.5%
Status Migrainosus 4.4%
Amniotic Fluid Volume Decreased 3.3%
Gallbladder Disorder 3.3%
Gallbladder Injury 3.3%
Insomnia 3.3%
Loss Of Consciousness 3.3%
Oedema Peripheral 3.3%
Pain 3.3%
Type 2 Diabetes Mellitus 3.3%
Abdominal Pain 2.2%